International audienceABSTRACT: BACKGROUND: PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) is a circulating protein that promotes hypercholesterolemia by decreasing hepatic LDL receptor protein. Under non interventional conditions, its expression is driven by sterol response element binding protein 2 (SREBP2) and follows a diurnal rhythm synchronous with cholesterol synthesis. Plasma PCSK9 is associated to LDL-C and to a lesser extent plasma triglycerides and insulin resistance. We aimed to verify the effect on plasma PCSK9 concentrations of dietary interventions that affect these parameters. METHODS: We performed nutritional interventions in young healthy male volunteers and offspring of type 2 diabetic (OffT2D) patients that are mo...
BACKGROUND: We measured plasma PCSK9 concentrations in healthy men with a PCSK9 (proprotein converta...
IntroductionProprotein convertase subtilisin kexin type 9 (PCSK9) is a natural inhibitor of the low ...
International audienceTotal word count (including tables and figure legends): 3927 Number of tables ...
International audienceABSTRACT: BACKGROUND: PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) is...
Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-pro...
International audienceI n order to assess the risk of cardiovascular diseases in patients, fasting p...
Purpose: Proprotein convertase subtilisin-kexin type 9 (PCSK9) promotes low density lipoprotein (LDL...
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) associates with cardiovascular disease indepen...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver damage and asso...
Purpose: Apolipoprotein M (apoM) retards atherosclerosis development in murine models, and may be re...
BACKGROUND: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) promotes the degradation of LDL re...
Objectives: Proprotein convertase subtilisin-kexin type 9 (PCSK9), a key regulator of low density li...
International audienceObjective: Increased postprandial lipemia (PPL) is an independent risk factor ...
International audienceBACKGROUND: Serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concen...
BACKGROUND: We measured plasma PCSK9 concentrations in healthy men with a PCSK9 (proprotein converta...
IntroductionProprotein convertase subtilisin kexin type 9 (PCSK9) is a natural inhibitor of the low ...
International audienceTotal word count (including tables and figure legends): 3927 Number of tables ...
International audienceABSTRACT: BACKGROUND: PCSK9 (Proprotein Convertase Subtilisin Kexin type 9) is...
Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-pro...
International audienceI n order to assess the risk of cardiovascular diseases in patients, fasting p...
Purpose: Proprotein convertase subtilisin-kexin type 9 (PCSK9) promotes low density lipoprotein (LDL...
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) associates with cardiovascular disease indepen...
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver damage and asso...
Purpose: Apolipoprotein M (apoM) retards atherosclerosis development in murine models, and may be re...
BACKGROUND: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) promotes the degradation of LDL re...
Objectives: Proprotein convertase subtilisin-kexin type 9 (PCSK9), a key regulator of low density li...
International audienceObjective: Increased postprandial lipemia (PPL) is an independent risk factor ...
International audienceBACKGROUND: Serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concen...
BACKGROUND: We measured plasma PCSK9 concentrations in healthy men with a PCSK9 (proprotein converta...
IntroductionProprotein convertase subtilisin kexin type 9 (PCSK9) is a natural inhibitor of the low ...
International audienceTotal word count (including tables and figure legends): 3927 Number of tables ...